Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 18/20 | 0.76 |
| ▸ | HTR2C | P28335 | 17/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.57 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034181 | 0.91 | HTR2A (0.63) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL2338740 | 0.85 | HTR2A (1.00) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL14625270 | 0.85 | HTR2A (0.76) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL16627265 | 0.81 | HTR2A (0.70) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL6034623 | 0.81 | HTR2A (0.72) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL4808088 | 0.80 | ALDH1A1 (0.50) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL4808083 | 0.80 | ALDH1A1 (0.50) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL14720872 | 0.80 | ALDH1A1 (0.50) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL12315354 | 0.79 | HTR2A (0.74) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL5466250 | 0.77 | GPR119 (0.53) | HTR2AHTR2CL3MBTL1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | claimed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | claimed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | claimed |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | HTR2A 210/4885HTR2C 350/4885L3MBTL1 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.